ATE59412T1 - Charakterisierung von onkogenen und darauf beruhende bestimmungen. - Google Patents

Charakterisierung von onkogenen und darauf beruhende bestimmungen.

Info

Publication number
ATE59412T1
ATE59412T1 AT83903635T AT83903635T ATE59412T1 AT E59412 T1 ATE59412 T1 AT E59412T1 AT 83903635 T AT83903635 T AT 83903635T AT 83903635 T AT83903635 T AT 83903635T AT E59412 T1 ATE59412 T1 AT E59412T1
Authority
AT
Austria
Prior art keywords
oncogenes
characterization
determinations based
carcinogenesis
detection
Prior art date
Application number
AT83903635T
Other languages
English (en)
Inventor
Robert A Weinberg
Clifford James Tabin
Scott M Bradley
Original Assignee
Massachusetts Inst Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Inst Technology filed Critical Massachusetts Inst Technology
Application granted granted Critical
Publication of ATE59412T1 publication Critical patent/ATE59412T1/de

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3038Kidney, bladder
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813Hybridisation assays
    • C12Q1/6827Hybridisation assays for detection of mutation or polymorphism
    • C12Q1/683Hybridisation assays for detection of mutation or polymorphism involving restriction enzymes, e.g. restriction fragment length polymorphism [RFLP]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531Production of immunochemical test materials
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00Chemistry: analytical and immunological testing
    • Y10S436/811Test for named disease, body condition or organ function
    • Y10S436/813Cancer
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y10S530/809Fused cells, e.g. hybridoma
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00Chemistry: analytical and immunological testing
    • Y10T436/14Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333Saccharide [e.g., DNA, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • External Artificial Organs (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
AT83903635T 1982-10-01 1983-09-29 Charakterisierung von onkogenen und darauf beruhende bestimmungen. ATE59412T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US06/432,337 US4535058A (en) 1982-10-01 1982-10-01 Characterization of oncogenes and assays based thereon
EP83903635A EP0120958B1 (de) 1982-10-01 1983-09-29 Charakterisierung von onkogenen und darauf beruhende bestimmungen
PCT/US1983/001517 WO1984001389A1 (en) 1982-10-01 1983-09-29 Characterization of oncogenes and assays based thereon

Publications (1)

Publication Number Publication Date
ATE59412T1 true ATE59412T1 (de) 1991-01-15

Family

ID=23715723

Family Applications (3)

Application Number Title Priority Date Filing Date
AT87200461T ATE115588T1 (de) 1982-10-01 1983-09-29 Ein verfahren zur herstellung eines antikörpers, der zur bestimmung der anwesenheit eines menschlichen oncogens befähigt ist.
AT87200460T ATE114820T1 (de) 1982-10-01 1983-09-29 Verfahren zur bestimmung von durch onkogene verursachten krebs.
AT83903635T ATE59412T1 (de) 1982-10-01 1983-09-29 Charakterisierung von onkogenen und darauf beruhende bestimmungen.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
AT87200461T ATE115588T1 (de) 1982-10-01 1983-09-29 Ein verfahren zur herstellung eines antikörpers, der zur bestimmung der anwesenheit eines menschlichen oncogens befähigt ist.
AT87200460T ATE114820T1 (de) 1982-10-01 1983-09-29 Verfahren zur bestimmung von durch onkogene verursachten krebs.

Country Status (6)

Country Link
US (3) US4535058A (de)
EP (4) EP0241961B1 (de)
JP (2) JPH0642840B2 (de)
AT (3) ATE115588T1 (de)
DE (3) DE3382765T2 (de)
WO (1) WO1984001389A1 (de)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4935341A (en) * 1986-06-04 1990-06-19 Whitehead Institute For Biomedical Research Detection of point mutations in neu genes
US6713619B1 (en) * 1980-08-29 2004-03-30 Massachusetts Institute Of Technology Oncogenes and methods for their detection
US4699877A (en) * 1982-11-04 1987-10-13 The Regents Of The University Of California Methods and compositions for detecting human tumors
USRE35491E (en) * 1982-11-04 1997-04-08 The Regents Of The University Of California Methods and compositions for detecting human tumors
US5591587A (en) * 1983-08-17 1997-01-07 The Scripps Research Institute Polypeptide-induced monoclonal receptors to protein ligands
US5733738A (en) * 1983-08-17 1998-03-31 Ligand Pharmaceuticals Polypeptide-induced monoclonal receptors to protein ligands
US5030565A (en) * 1983-08-17 1991-07-09 Scripps Clinic And Research Foundation Polypeptide-induced monoclonal receptors to protein ligands
US4681840A (en) * 1984-01-18 1987-07-21 The United States Of America As Represented By The Secretary Of Commerce Deoxyribonucleic acid molecules useful as probes for detecting oncogenes incorporated into chromosomal DNA
US4725550A (en) * 1984-01-19 1988-02-16 Research Foundation Of State University Of New York Novel mutation of the c-K-ras oncogene activated in a human lung carcinoma
US4683194A (en) * 1984-05-29 1987-07-28 Cetus Corporation Method for detection of polymorphic restriction sites and nucleic acid sequences
US4736866B1 (en) * 1984-06-22 1988-04-12 Transgenic non-human mammals
US5087571A (en) * 1984-06-22 1992-02-11 President And Fellows Of Harvard College Method for providing a cell culture from a transgenic non-human mammal
US4866166A (en) * 1984-08-31 1989-09-12 Cold Spring Harbor Laboratory Bioassay for transforming genes and genes detected thereby
EP0177814A3 (de) * 1984-09-19 1987-12-02 Cetus Corporation Antikörper gegen Peptide und ihre Verwendung zum Nachweis von Onkogene-Produkten
US4762706A (en) * 1984-10-17 1988-08-09 Cetus Corporation Peptide antibodies and their use in detecting oncogene products
US4798787A (en) * 1984-09-19 1989-01-17 Cetus Corporation Peptide antibodies and their use in detecting oncogene products
US4701409A (en) * 1984-11-15 1987-10-20 The Wistar Institute Detection of B-cell neoplasms
US4735895A (en) * 1984-12-28 1988-04-05 Oncotech, Inc. Cancer susceptibility test
US5443956A (en) * 1985-01-29 1995-08-22 Oncogene Science, Inc. Detection, quantitation and classification of RAS proteins in body fluids and tissues
US6200764B1 (en) 1985-01-29 2001-03-13 Bayer Corporation Detection, quantitation and classification of ras proteins in body fluids and tissues
US5081230A (en) * 1987-07-08 1992-01-14 E. I. Dupont Denemours And Company Monoclonal antibodies reactive with normal and oncogenic forms of the ras p21 protein
US5028527A (en) * 1988-02-22 1991-07-02 Applied Bio Technology Monoclonal antibodies against activated ras proteins with amino acid mutations at position 13 of the protein
CA1296660C (en) * 1985-01-29 1992-03-03 Walter P. Carney Monoclonal antibody against a ras oncogene p21 related dodecapeptide
US4898932A (en) * 1985-01-29 1990-02-06 E. I. Du Pont De Nemours And Company Monoclonal antibodies reactive with activated and oncogenic ras p21 proteins
US5084380A (en) * 1985-01-29 1992-01-28 Applied Biotechnology Monoclonal antibodies reactive with activated and oncogenic ras p21 proteins
WO1986006494A2 (fr) * 1985-05-02 1986-11-06 Pasteur Institut Moyens pour le diagnostic in vitro de cellules malignesorigi naires du tube digestif
FR2589882B2 (fr) * 1985-11-13 1988-01-15 Pasteur Institut Moyens pour le diagnostic in vitro de cellules malignes originaires du tube digestif
US5635389A (en) * 1985-05-02 1997-06-03 Institut Pasteur Antibodies which recognize and bind human villin
US4871838A (en) * 1985-07-23 1989-10-03 The Board Of Rijks Universiteit Leiden Probes and methods for detecting activated ras oncogenes
US5591582A (en) * 1985-07-23 1997-01-07 The Board Of Rijks Universiteit Leiden Methods for detecting activated RAS oncogenes
US6083709A (en) * 1985-08-21 2000-07-04 Osi Pharmaceuticals, Inc. Immunoassay for detection of mutant P53 polypeptide in serum
US4946773A (en) * 1985-12-23 1990-08-07 President And Fellows Of Harvard College Detection of base pair mismatches using RNAase A
US5320941A (en) * 1986-06-06 1994-06-14 Dallan Young DNA sequence encoding mas onhcogene, polypeptides encoded therefrom and diagnostic and other methods based therefrom
US5015568A (en) * 1986-07-09 1991-05-14 The Wistar Institute Diagnostic methods for detecting lymphomas in humans
US4820631A (en) * 1986-07-30 1989-04-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Deletion mutants and monoclonal antibodies against ras proteins
US7223842B1 (en) 1986-08-11 2007-05-29 Massachusetts Eye And Ear Infirmary Detection of proteins whose absence is associated with a neoplasm
CA1341576C (en) * 1986-08-11 2008-07-08 Thaddeus P. Dryja Diagnosis of retinoblastoma
US5853988A (en) * 1986-08-11 1998-12-29 Massachusetts Eye And Ear Infirmary Diagnosis of retinoblastoma
US7384735B1 (en) 1986-08-11 2008-06-10 Massachusetts Eye And Ear Infirmary Retinoblastoma nucleic acids
WO1988002404A1 (en) * 1986-09-30 1988-04-07 Smithkline Beckman Corporation Cell transfection
US4968603A (en) * 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
US5789235A (en) * 1987-03-23 1998-08-04 Tackett; Scott E. Modifying cell metabolism via extra-cellular nucleases
US4870161A (en) * 1987-09-25 1989-09-26 The United States Of America As Represented By The Department Of Health And Human Services Reagents and probes for distinguishing and isolating different GTP-binding proteins
CA1339069C (en) * 1987-11-09 1997-07-29 Henry Lee Niman Polypeptide-induced monoclonal receptors to protein ligand
US4957859A (en) * 1988-02-16 1990-09-18 Hoffmann-La Roche Inc. Antibodies for transforming ras protein
US5112737A (en) * 1988-02-22 1992-05-12 Applied Biotechnology, Inc. Monoclonal antibodies against activated ras proteins with amino acid mutations at position 13 of the protein
DE3844964C2 (de) * 1988-03-22 1997-02-13 Niehoff Kg Maschf Verfahren zum Abzug eines Gebindes aus strangförmigem Gut
JPH0816679B2 (ja) 1988-04-22 1996-02-21 オンコジーン・サイエンス・インコーポレーテッド 体液および組織におけるrasタンパクの検出、定量および分類
WO1989012697A1 (en) * 1988-06-22 1989-12-28 The Board Of Regents Of The University Of Washingt Method for detecting abnormal genes
US5760203A (en) * 1988-08-10 1998-06-02 Chiron Corporation Gap gene sequences
US5763573A (en) * 1988-08-10 1998-06-09 Chiron Corporation GTPase activating protein fragments
FR2645877B1 (fr) * 1989-04-12 1991-07-05 Pasteur Institut Molecules comportant au moins une sequence peptidique porteuse d'un, ou plusieurs, epitope caracteristique d'une proteine produite par p. falciparum au niveau du stade sporozoite et dans les hepatocytes
US5776502A (en) 1989-07-18 1998-07-07 Oncogene Science, Inc. Methods of transcriptionally modulating gene expression
US6203976B1 (en) 1989-07-18 2001-03-20 Osi Pharmaceuticals, Inc. Methods of preparing compositions comprising chemicals capable of transcriptional modulation
US5580722A (en) * 1989-07-18 1996-12-03 Oncogene Science, Inc. Methods of determining chemicals that modulate transcriptionally expression of genes associated with cardiovascular disease
US5665543A (en) * 1989-07-18 1997-09-09 Oncogene Science, Inc. Method of discovering chemicals capable of functioning as gene expression modulators
AU660405B2 (en) * 1989-07-18 1995-06-29 Osi Pharmaceuticals, Inc. Method of transcriptionally modulating gene expression and of discovering chemicals capable of functioning as gene expression modulators
ES2264239T3 (es) * 1990-06-27 2006-12-16 Princeton University Complejo de proteinas p53/p90'.
US6159751A (en) * 1990-10-25 2000-12-12 The Trustees Of Columbia University In The City Of New York Development of DNA probes and immunological reagents of human tumor associated antigens
US5851764A (en) * 1990-10-25 1998-12-22 The Trustees Of Columbia University In The City Of New York Human prostate tumor inducing gene-1 and uses thereof
AU660001B2 (en) * 1990-10-25 1995-06-08 Trustees Of Columbia University In The City Of New York, The Development of DNA probes and immunological reagents of human tumor associated antigens
AU1536392A (en) * 1991-01-18 1992-08-27 Oncogene Science, Inc. Methods of transcriptionally modulating expression of oncogenes and tumor suppressor genes
US6110700A (en) * 1991-03-11 2000-08-29 The General Hospital Corporation PRAD1 cyclin and its cDNA
US6150398A (en) * 1991-05-08 2000-11-21 The United States Of America As Represented By The Department Of Health And Human Services Methods for the treatment of cancer
US5468634A (en) * 1991-06-24 1995-11-21 The University Of North Carolina At Chapel Hill Axl oncogene
WO1993022457A1 (en) * 1992-04-24 1993-11-11 Massachusetts Institute Of Technology Screening for genetic variation
US6965009B1 (en) 1993-08-02 2005-11-15 Health Research, Inc. p53 as protein and antibody therefor
US5688918A (en) * 1993-08-02 1997-11-18 Health Research, Inc. p53as protein and antibody therefor
US5747650A (en) * 1993-08-02 1998-05-05 Health Research, Inc. P53AS protein and antibody therefor
US5726024A (en) * 1993-08-02 1998-03-10 Health Research, Inc. p53as protein and antibody therefor
AU1094795A (en) * 1993-11-12 1995-05-29 Oncor, Inc. Detection of bladder cancer
US5670325A (en) * 1996-08-14 1997-09-23 Exact Laboratories, Inc. Method for the detection of clonal populations of transformed cells in a genomically heterogeneous cellular sample
US5741650A (en) * 1996-01-30 1998-04-21 Exact Laboratories, Inc. Methods for detecting colon cancer from stool samples
US6524578B1 (en) 1996-07-10 2003-02-25 Scott E. Tackett Use of nuclease to reduce wrinkles and discolorations in humans
US6203993B1 (en) 1996-08-14 2001-03-20 Exact Science Corp. Methods for the detection of nucleic acids
US6020137A (en) * 1996-08-14 2000-02-01 Exact Laboratories, Inc. Methods for the detection of loss of heterozygosity
US6300077B1 (en) 1996-08-14 2001-10-09 Exact Sciences Corporation Methods for the detection of nucleic acids
US6146828A (en) * 1996-08-14 2000-11-14 Exact Laboratories, Inc. Methods for detecting differences in RNA expression levels and uses therefor
US6100029A (en) * 1996-08-14 2000-08-08 Exact Laboratories, Inc. Methods for the detection of chromosomal aberrations
US5952178A (en) * 1996-08-14 1999-09-14 Exact Laboratories Methods for disease diagnosis from stool samples
US5928870A (en) * 1997-06-16 1999-07-27 Exact Laboratories, Inc. Methods for the detection of loss of heterozygosity
US6300081B1 (en) 1996-11-15 2001-10-09 Cornell Research Foundation, Inc. Activated ras interaction assay
US6268136B1 (en) 1997-06-16 2001-07-31 Exact Science Corporation Methods for stool sample preparation
US6406857B1 (en) 1997-06-16 2002-06-18 Exact Sciences Corporation Methods for stool sample preparation
US20020064792A1 (en) * 1997-11-13 2002-05-30 Lincoln Stephen E. Database for storage and analysis of full-length sequences
US6280947B1 (en) 1999-08-11 2001-08-28 Exact Sciences Corporation Methods for detecting nucleotide insertion or deletion using primer extension
US6503718B2 (en) 1999-01-10 2003-01-07 Exact Sciences Corporation Methods for detecting mutations using primer extension for detecting disease
US6551777B1 (en) 1999-02-25 2003-04-22 Exact Sciences Corporation Methods for preserving DNA integrity
US6964846B1 (en) * 1999-04-09 2005-11-15 Exact Sciences Corporation Methods for detecting nucleic acids indicative of cancer
US6586177B1 (en) * 1999-09-08 2003-07-01 Exact Sciences Corporation Methods for disease detection
US6849403B1 (en) 1999-09-08 2005-02-01 Exact Sciences Corporation Apparatus and method for drug screening
US6919174B1 (en) 1999-12-07 2005-07-19 Exact Sciences Corporation Methods for disease detection
WO2001042781A2 (en) * 1999-12-07 2001-06-14 Exact Sciences Corporation Supracolonic aerodigestive neoplasm detection
US7776524B2 (en) 2002-02-15 2010-08-17 Genzyme Corporation Methods for analysis of molecular events
US20040259101A1 (en) * 2003-06-20 2004-12-23 Shuber Anthony P. Methods for disease screening
US8969372B2 (en) 2003-11-14 2015-03-03 Aptose Boisciences Inc. Aryl imidazoles and their use as anti-cancer agents
WO2005111244A2 (en) * 2004-05-10 2005-11-24 Exact Sciences Corporation Methods for detecting a mutant nucleic acid
WO2005113769A1 (en) * 2004-05-14 2005-12-01 Exact Sciences Corporation Method for stabilizing biological samples for nucleic acid analysis
WO2006026654A2 (en) 2004-08-27 2006-03-09 Exact Sciences Corporation Method for detecting a recombinant event
WO2006047787A2 (en) 2004-10-27 2006-05-04 Exact Sciences Corporation Method for monitoring disease progression or recurrence
DE102005011022A1 (de) * 2005-03-10 2006-09-14 Häfner & Krullmann Gmbh Verfahren zum Bewickeln einer Spule mit strangförmigem Wickelgut
US9777314B2 (en) * 2005-04-21 2017-10-03 Esoterix Genetic Laboratories, Llc Analysis of heterogeneous nucleic acid samples
WO2007025044A2 (en) * 2005-08-24 2007-03-01 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators
KR20160058960A (ko) 2013-10-04 2016-05-25 압토스 바이오사이언시스 인코포레이티드 암을 치료하기 위한 조성물과 방법
KR20190008415A (ko) * 2016-06-10 2019-01-23 브록 라이덴 상처 패킹을 이용한 상처 치료 시스템 및 방법
AU2018360477A1 (en) 2017-10-30 2020-06-04 Aptose Biosciences Inc. Aryl imidazoles for the treatment of cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4299815A (en) * 1980-02-08 1981-11-10 Hoffmann-La Roche Inc. Carcinoembryonic antigen determination
US4368262A (en) * 1981-03-23 1983-01-11 Research Corporation Diagnostic test for the detection of cancer
US4395486A (en) * 1981-08-19 1983-07-26 Medical College Of Ga. Research Inst., Inc. Method for the direct analysis of sickle cell anemia

Also Published As

Publication number Publication date
JPH0642840B2 (ja) 1994-06-08
JPS60500002A (ja) 1985-01-10
EP0241961B1 (de) 1994-11-30
WO1984001389A1 (en) 1984-04-12
EP0241961A3 (en) 1989-01-25
US4786718A (en) 1988-11-22
JP2573770B2 (ja) 1997-01-22
DE3382765D1 (de) 1995-01-12
DE3382767D1 (de) 1995-01-26
EP0239162B1 (de) 1994-12-14
DE3382098D1 (de) 1991-02-07
ATE115588T1 (de) 1994-12-15
US4535058A (en) 1985-08-13
EP0241961A2 (de) 1987-10-21
EP0120958A1 (de) 1984-10-10
EP0120958B1 (de) 1990-12-27
DE3382765T2 (de) 1995-05-04
US5300631A (en) 1994-04-05
EP0239162A2 (de) 1987-09-30
JPH05281228A (ja) 1993-10-29
ATE114820T1 (de) 1994-12-15
EP0605789A1 (de) 1994-07-13
DE3382767T2 (de) 1995-10-19
EP0239162A3 (en) 1989-08-16

Similar Documents

Publication Publication Date Title
ATE59412T1 (de) Charakterisierung von onkogenen und darauf beruhende bestimmungen.
DE3689619D1 (de) Verfahren und vorrichtung zur bestimmung der konzentration von asphalten.
DE59405820D1 (de) Verfahren zur Ermittlung charakteristischer Eigenschaften von Radikale bildenden Prozessen
ATE200151T1 (de) Analytische testvorrichtung einschliesslich negativ- und positivkontrolle
DE3583620D1 (de) Vorrichtung zur photoakustischen detektion von gasen.
DE3576853D1 (de) Ultraschall-koagulationsanzeiger und methode zum nachweis des eintretens von koagulation.
ATE26487T1 (de) Einrichtung zur feststellung und zahlenmaessigen auswertung von agglutinaten.
DE3789430D1 (de) Homogenes fluortestverfahren mit abstoss des fluorzenten hintergrundes.
DE3687328D1 (de) Vorort-bestimmung des gesamtkohlenstoffgehalts zur auswertung von muttergestein.
DE69110032D1 (de) Verfahren und Gerät zur Feststellung und/oder Konzentrationsbestimmung von Biomolekülen.
ATE167524T1 (de) Verfahren zum nachweis, identifizieren und quantifizieren von organismen und viren
DE3482878D1 (de) Vorrichtung zur erfassung, messtechnischen analyse und/oder regelung von technischen verfahrensablaeufen.
BR8604929A (pt) Detector de desgaste ferromagnetico e metodo para determinar o grau de desgaste
DE3884456D1 (de) Vorrichtung zur detektion und richtungsbestimmung von licht.
DE69005069D1 (de) Vorrichtung zur Feststellung des Vorhandenseins von fremden Stoffen.
ES2076976T3 (es) Metodo para detectar carcinomas de celulas pequeñas y utilizacion de secuencias que codifican acil-peptido hidrolasa para el mismo.
DE3683059D1 (de) Verfahren und geraet zur konzentrationsmessung von halogen-ionen.
DE3263152D1 (en) Reagents for determining the ristocetin cofactor (von willebrand's factor)
FI844645L (fi) 1,7-difenyl-3-metylaza-7-cyan-8 -metyl-nonan foer anvaendning vid bekaempning av sjukdomar.
DE69014512D1 (de) Reagens zum Nachweis von Bilirubin in Urin.
ZA865767B (en) Homogeneous process for the detection and/or determination by luminescence of an analyte in a medium in which it may be present
ATE64470T1 (de) Verfahren und zusammensetzungen zur bestimmung von heparin.
DE3786322D1 (de) Vorrichtung zur automatischen bestimmung von kenngroessen von textilem pruefgut.
DE3544568A1 (de) Vorrichtung zur bestimmung des absolutwerts der konzentration von salzen in der atmosphaere
SE8504913L (sv) Forfarande och anordning for kantdetektering av provobjekt

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time